Ocular Therapeutix Names Namrata Saroj as Chief Business Officer
Ocular Therapeutix announced that Namrata Saroj, OD, has joined the company as Chief Business Officer (CBO).
Dr. Saroj, who has been consulting with Ocular since February 2024, brings extensive experience in clinical development and commercialization in ophthalmology. She contributed to the development of FDA-approved therapies such as Lucentis and Eylea, two breakthrough treatments for retinal diseases. As Chief Business Officer, she will focus on advancing Ocular’s strategic initiatives, including the development of Axpaxli, the company’s therapy targeting wet AMD.
“I am thrilled to further strengthen and enrich Ocular’s senior leadership team with Namrata as Chief Business Officer. She brings a unique perspective to the role based on her impressive track record in clinical development, launch preparation, and commercialization," Pravin U. Dugel, MD, Executive Chairman, President, and CEO of Ocular Therapeutix, said in a company news release. "Namrata has played a pivotal role in enhancing the effective execution of our registrational program for Axpaxli in wet age-related macular degeneration.”
“I joined Ocular to leverage my expertise in ophthalmology drug development and to advance therapies for retinal diseases,” said Dr. Saroj. “The mission of improving vision for patients has always been at the heart of my work, and I am excited to dedicate myself to Ocular full-time. I look forward to collaborating with this top-notch team of retina experts to drive our commercial strategies and expand our pipeline.”
Dr. Saroj brings over 20 years of experience in the global development and commercialization of ophthalmic drugs and technologies. She was integral to the success of several pharmaceutical companies, working across early-stage start-ups to late-stage commercialization. Her expertise includes strategic partnerships, clinical trial design, trial enrollment, and commercialization efforts. Before joining Ocular, Dr. Saroj co-founded the Clinical Trials Resource Group, a contract research organization focused on executing ophthalmology clinical trials. Her previous roles include Executive Director of Ophthalmology Medical Affairs at Regeneron Pharmaceuticals, as well as key positions at Genentech, and the Manhattan Eye, Ear & Throat Hospital.
She has also co-authored numerous peer-reviewed publications on the management of retinal diseases and currently serves as President of the Association for Macular Diseases, a non-profit organization supporting individuals affected by retinal disorders.